[Skip to Navigation]
Sign In

October 2021 - April 2015

Decade

Year

Issue

December 2016, Vol 2, No. 12, Pages 1519-1667

Original Investigation

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

Abstract Full Text
free access has audio
JAMA Oncol. 2016;2(12):1557-1564. doi:10.1001/jamaoncol.2016.0237

The NEfERT-T randomized clinical trial seeks to determine whether neratinib plus paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel in the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer in a cohort of 479 women.

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

Abstract Full Text
open access
JAMA Oncol. 2016;2(12):1565-1573. doi:10.1001/jamaoncol.2016.0891

This molecular pathology study characterizes patterns of genetic alterations in phosphatidylinositol-3-kinase pathway components in solid tumor specimens that point toward opportunities for targeted therapy.

Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1574-1581. doi:10.1001/jamaoncol.2016.2547

This cancer epidemiology study uses National Cancer Data Base data to characterize trends in use of postoperative radiotherapy for children ages 3 to 8 years with medulloblastoma, and clinical variables associated with treatment and survival.

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2016;2(12):1583-1589. doi:10.1001/jamaoncol.2016.2520

This follow-up of a randomized clinical trial compares patient-reported outcomes between patients randomized to receive unrelated donor bone marrow or peripheral blood hematopoietic cell transplantation for hematologic cancers.

Cardiovascular Disease After Aromatase Inhibitor Use

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1590-1597. doi:10.1001/jamaoncol.2016.0429

This cohort study compares the risk of cardiovascular disease in breast cancer survivors who received tamoxifen, aromatase inhibitors, both, or neither during a long-term follow-up period.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1598-1606. doi:10.1001/jamaoncol.2016.0494

This genomic profiling study investigates the genomic mechanisms underpinning resistance to the androgen receptor antagonist enzalutamide in metastatic castration-resistant prostate cancer.

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1607-1616. doi:10.1001/jamaoncol.2016.2453

This meta-analysis summarizes the incidence of PD-1 inhibitor–related pneumonitis in patients with advanced cancer by tumor type and therapeutic regimen.

Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1617-1623. doi:10.1001/jamaoncol.2016.1804

This study uses SEER data to compare trends in incidence of oropharyngeal cancer, tobacco-related cancers, and HPV-related anal cancer in elderly patients between 2000 and 2012.

Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1624-1627. doi:10.1001/jamaoncol.2016.3651

This Danish nationwide cohort study evaluates the treatment-specific risks for second malignant neoplasms and death in patients with testicular germ cell cancer treated with current standard regimens.

Brief Report

Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1628-1631. doi:10.1001/jamaoncol.2016.2710

This study uses CMS’s Open Payments Database data to describe the prevalence of financial conflicts of interest among authors of recent National Comprehensive Cancer Network guidelines.

Research Letter

Effect of the American Society of Clinical Oncology’s Conflict of Interest Policy on Information Overload

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1653-1654. doi:10.1001/jamaoncol.2016.2706

This study of American Society of Clinical Oncology (ASCO) 2014-15 meeting videos characterizes the word count of financial conflict of interest disclosures appearing in slide presentations in response to a policy requiring the disclosure.

Use of Online Communication by Patients With Newly Diagnosed Breast Cancer During the Treatment Decision Process

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1654-1656. doi:10.1001/jamaoncol.2016.2070

This survey study explores whether and how women with newly diagnosed breast cancer use online communication during the cancer treatment decision-making process.

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1656-1657. doi:10.1001/jamaoncol.2016.2437

This study examines whether B cells in patients with chronic lymphocytic leukemia receiving ibrutinib can mount a humoral immune response to seasonal influenza vaccination.

Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1657-1660. doi:10.1001/jamaoncol.2016.2667

This cancer epidemiology study uses SEER database data to examine whether early-stage prostate cancer incidence rates continued their 2011 to 2012 decline in 2013.

Review

The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review

Abstract Full Text
JAMA Oncol. 2016;2(12):1636-1642. doi:10.1001/jamaoncol.2016.2631

This perspective discusses the advent of medical imaging as a data source for precision management of patients with cancer through integration of automated imaging phenotype and cancer genotype.

JAMA Oncology Clinical Evidence Synopsis

Chemotherapy for Advanced Non–Small-Cell Lung Cancer in Elderly Patients

Abstract Full Text
JAMA Oncol. 2016;2(12):1645-1646. doi:10.1001/jamaoncol.2016.2050

This clinical evidence synopsis summarizes a Cochrane systematic review evaluating the effect of nonplatinum chemotherapy vs a platinum-based combination and a nonplatinum single-agent vs a nonplatinum combination in patients older than 70 years with advanced non–small-cell lung cancer.

Medical and Surgical Treatments for Usual-Type Vulvar Intraepithelial Neoplasia

Abstract Full Text
JAMA Oncol. 2016;2(12):1647-1648. doi:10.1001/jamaoncol.2016.2430

This Clinical Evidence Synopsis summarizes a recent Cochrane review update on interventions for high-grade vulvar intraepithelial neoplasia.

JAMA Oncology Clinical Challenge

Skin Lesions and Recurrent Fever in Acute Myeloid Leukemia Patient Treated With Allogeneic Stem Cell Transplant

Abstract Full Text
JAMA Oncol. 2016;2(12):1649-1650. doi:10.1001/jamaoncol.2016.2433

A 69-year-old man with a history of relapsed acute myeloid leukemia monocytic type presented with intermittent fever and fatigue 2 months after allogeneic stem cell transplantation; home medications included acyclovir, fluconazole, and cyclosporine. What is your diagnosis?

Respiratory Failure in a Woman 8 Months After an Allogeneic Stem Cell Transplant

Abstract Full Text
JAMA Oncol. 2016;2(12):1651-1652. doi:10.1001/jamaoncol.2016.2642

A 67-year-old woman with peripheral T-cell lymphoma after an allogeneic stem cell transplant on empirical broad-spectrum antibiotics for dyspnea and bilateral CXR opacities develops respiratory failure and diffuse ground-glass opacities on CT scan. What would you do next?

Viewpoint

Intermittent Androgen Deprivation Therapy—An Important Treatment Option for Prostate Cancer

Abstract Full Text
JAMA Oncol. 2016;2(12):1531-1532. doi:10.1001/jamaoncol.2016.3138

This Viewpoint argues in favor of a role for intermittent androgen deprivation therapy for management of men with prostate cancer.

Intermittent Androgen Deprivation: Primum Non Nocere—“First Do NO Harm”

Abstract Full Text
JAMA Oncol. 2016;2(12):1533-1534. doi:10.1001/jamaoncol.2016.2650

This Viewpoint argues against a continued role for intermittent androgen-deprivation therapy in the management of men with prostate cancer.

Annual Meeting Highlights

Highlights in Central Nervous System Tumors

Abstract Full Text
JAMA Oncol. 2016;2(12):1535-1536. doi:10.1001/jamaoncol.2016.3673

This Viewpoint highlights recent findings in the treatment of central nervous system tumors.

Annual Meeting Highlights

Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy

Abstract Full Text
JAMA Oncol. 2016;2(12):1537-1538. doi:10.1001/jamaoncol.2016.3642

This Viewpoint highlights recent study findings about the treatment of gastrointestinal (colorectal) cancer.

Heavy Ions in Cancer Therapy

Abstract Full Text
JAMA Oncol. 2016;2(12):1539-1540. doi:10.1001/jamaoncol.2016.2646

This Viewpoint compares the advantages and disadvantages of x-ray, proton, and heavy-ion therapy in cancer treatment, and the future of heavy-ion therapy in the United States.

From the JAMA Network

Size Matters in Chest Tubes—Efficacy of Analgesia and Pleurodesis in Patients With Malignant Pleural Effusion

Abstract Full Text
JAMA Oncol. 2016;2(12):1643-1644. doi:10.1001/jamaoncol.2016.1148

This commentary discusses a trial published in JAMA that compared the effects of chest tube size and analgesia types on pain and efficacy of pleurodesis for management of malignant pleural effusion.

Editorial

Neratinib in ERBB2-Positive Brain Metastases

Abstract Full Text
JAMA Oncol. 2016;2(12):1541-1543. doi:10.1001/jamaoncol.2016.0238

PI3 Kinase Pathway Mutations in Human Cancers

Abstract Full Text
JAMA Oncol. 2016;2(12):1543-1544. doi:10.1001/jamaoncol.2016.0875

Announcing the New JAMAOncology.com

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1544-1546. doi:10.1001/jamaoncol.2016.5037
Invited Commentary

Radiotherapy Deferral in Medulloblastoma

Abstract Full Text
JAMA Oncol. 2016;2(12):1582. doi:10.1001/jamaoncol.2016.2546

No Conflict, No Interest

Abstract Full Text
JAMA Oncol. 2016;2(12):1631-1632. doi:10.1001/jamaoncol.2016.2726
JAMA Oncology Patient Page

Intimacy, Body Image, and Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1667. doi:10.1001/jamaoncol.2016.1196
Comment & Response

Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors

Abstract Full Text
JAMA Oncol. 2016;2(12):1660. doi:10.1001/jamaoncol.2016.4919

Transparency or Independence in Conflict of Interest Disclosures

Abstract Full Text
JAMA Oncol. 2016;2(12):1661. doi:10.1001/jamaoncol.2016.4908
Correction

Error in Results Section

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1661. doi:10.1001/jamaoncol.2016.4310
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1521. doi:10.1001/jamaoncol.2015.3555
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(12):1519. doi:10.1001/jamaoncol.2015.3554
×